{"id":"W4281848556","doi":"10.1016/j.jacl.2022.05.067","title":"Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT","year":2022,"lang":"en","type":"review","venue":"Journal of clinical lipidology","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"St. Jude Medical; Esperion Therapeutics; HLS Therapeutics; Idorsia Pharmaceuticals; Daiichi Sankyo Europe; Servier; Assistance publique-Hôpitaux de Paris; Pfizer; Moderna; Medicines Company; Regado Biosciences; Belvoir Media Group; MyoKardia; Novo Nordisk; AstraZeneca; Amarin Corporation; Ironwood Pharmaceuticals, Incorporated; Regeneron Pharmaceuticals; Duke Clinical Research Institute; Eisai; Brigham and Women's Hospital; Boston VA Research Institute; Boston Scientific Corporation; Eli Lilly and Company; Cleveland Clinic; Bristol-Myers Squibb; CSL Behring; Novartis; Amgen; Sanofi; American Heart Association","keywords":"Medicine; Residual risk; Hypertriglyceridemia; Myocardial infarction; Internal medicine; Cardiology; Revascularization; Clinical endpoint; Randomized controlled trial; Stroke (engine); Triglyceride; Cholesterol","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002337867,0.001015453,0.003680051,0.002408381,0.0002131825,0.001174489,0.00141812,0.001098154,0.003038031],"category_scores_gemma":[0.004773806,0.0004357693,0.001987841,0.002433852,0.0004710192,0.001004791,0.0006158964,0.001591865,0.000636186],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006805579,"about_ca_system_score_gemma":0.001856371,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001303255,"about_ca_topic_score_gemma":0.002485942,"domain_scores_codex":[0.9994411,0.0001265975,0.0001911145,0.00008971986,0.0001233975,0.00002806113],"domain_scores_gemma":[0.9972306,0.002149215,0.0002774029,0.00003678253,0.0002523617,0.00005367427],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000656675,0.00008144221,0.0002081247,0.2973705,0.00178253,0.0001248798,0.00009525954,0.0002187311,0.0007388485,0.001323705,0.01473488,0.6826645],"study_design_scores_gemma":[0.0007766873,0.001209731,0.004232854,0.2599245,0.01409022,0.001421005,0.0002660375,0.0002562692,0.001112308,0.002951171,0.7136559,0.0001033565],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00007309221,0.9995316,0.00003656017,0.0001363363,0.00007261241,0.00001211118,0.00002540713,0.000002419917,0.0001097317],"genre_scores_gemma":[0.0005470929,0.999005,0.0001176041,0.0001909552,0.00005103644,0.00001779453,0.00002268524,0.000001273365,0.00004665108],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003680051,"threshold_uncertainty_score":0.01236403,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1941017303857026,"score_gpt":0.4499473697340759,"score_spread":0.2558456393483733,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}